Effects of weekly bevacizumab and pegylated liposomal doxorubicin in heavily pretreated patients with recurrent or progressed ovarian cancer

被引：0
|
作者：
Kikuchi, Y., Sr. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Kouta, H. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Kikuchi, R. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Takano, M. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Kita, T. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Kudoh, K. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Aoki, D. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Sugiyama, T. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Isonishi, S. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
机构：
[1] Ohki Mem Kikuchi Canc Clin Women, Tokorozawa, Saitama, Japan
[2] Natl Def Med Coll, Tokorozawa, Saitama 359, Japan
[3] Teikyo Univ, Sch Med, Tokyo 173, Japan
[4] Nishisaitama Cent Hosp, Tokorozawa, Saitama, Japan
[5] Keio Univ, Sch Med, Tokyo, Japan
[6] Iwate Med Univ, Morioka, Iwate 020, Japan
[7] Jikei Univ, Sch Med, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5547
引用
收藏
页数：2
相关论文
共 50 条
  • [41] PROLONGED TREATMENT WITH TRABECTIN PLUS PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) COMBINATION IN A HEAVILY PRETREATED PATIENT WITH METASTATIC RELAPSED OVARIAN CANCER (ROC)
    Guillet, P.
    Beedassy, B.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (09) : 1369 - 1369
  • [42] The role of bevacizumab in combination with pegylated liposomal doxorubicin in patients with platinum-resistant recurrent or refractory ovarian cancers.
    Kouta, H.
    Kudoh, K.
    Takano, M.
    Kikuchi, R.
    Kita, T.
    Goto, T.
    Furuya, K.
    Kikuchi, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [43] Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer
    O'Malley, David M.
    Richardson, Debra L.
    Rheaume, Patrick S.
    Salani, Ritu
    Eisenhauer, Eric L.
    McCann, Georgia A.
    Fowler, Jeffrey M.
    Copeland, Larry J.
    Cohn, David E.
    Backes, Floor J.
    GYNECOLOGIC ONCOLOGY, 2011, 121 (02) : 269 - 272
  • [44] Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated, recurrent epithelial ovarian cancer
    Hurt, J.
    Backes, F.
    Rheaume, S.
    Richardson, D.
    Fowler, J.
    Copeland, L.
    Cohn, D.
    Eisenhauer, E.
    Salani, R.
    O'Malley, D.
    GYNECOLOGIC ONCOLOGY, 2010, 116 (03) : S47 - S47
  • [45] Beyond the bevacizumab resistance, combined effects of erlotinib in heavily pretreated patients with recurrent ovarian cancers.
    Kikuchi, Yoshihiro
    Takano, Masashi
    Ikeda, Yuji
    Kikuchi, Ryoko
    Kudoh, Kazuya
    Sasaki, Naoki
    Sakamoto, Masaru
    Kita, Tsunekazu
    Terao, Yasuhisa
    Takeda, Satoru
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [46] Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer
    Markman, Maurie
    GYNECOLOGIC ONCOLOGY, 2012, 124 (01) : 171 - 171
  • [47] Pembrolizumab in combination with bevacizumab and pegylated liposomal doxorubicin in patients with platinum-resistant epithelial ovarian cancer.
    Michels, Judith
    Ghiringhelli, Francois
    Frenel, Jean-Sebastien
    Brard, Caroline
    You, Benoit
    Floquet, Anne
    Eberst, Lauriane
    Bahleda, Rastilav
    Genestie, Catherine
    Balleyguier, Corinne
    Broutin, Sophie
    Pautier, Patricia
    Colomba, Emeline
    Pommeret, Fanny
    Massard, Christophe
    Marabelle, Aurelien
    Leary, Alexandra
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [48] Non-pegylated liposomal doxorubicin for patients with recurrent ovarian cancer: A multicentric phase II trial
    Brucker, Janina
    Mayer, Christine
    Gebauer, Gerhard
    Mallmann, Peter
    Belau, Antje Kristina
    Schneeweiss, Andreas
    Sohn, Christof
    Eichbaum, Michael
    ONCOLOGY LETTERS, 2016, 12 (02) : 1211 - 1215
  • [49] The Safety of Pegylated Liposomal Doxorubicin Plus Irinotecan in Recurrent Ovarian Cancer Patients: A Phase I Trial
    Miyahara, Daisuke
    Ueda, Taeko
    Katsuda, Takahiro
    Maehara, Miyako
    Fukagawa, Satoshi
    Miyata, Kohei
    Nam, Sung Ouk
    Kondo, Haruhiko
    Miyamoto, Shingo
    ANTICANCER RESEARCH, 2015, 35 (08) : 4521 - 4525
  • [50] THE EFFECT OF SINGLE WEEKLY PACLITAXEL IN HEAVILY PRETREATED OVARIAN CANCER PATIENTS AND ITS ANTIANGIOGENIC EFFECTS
    Kikuchi, Yoshihiro
    Kita, Tsunekazu
    Takano, Masashi
    Kudoh, Kazuya
    Saito, Keiko
    Fujii, Kazuyuki
    Sasaki, Naoki
    ANTICANCER RESEARCH, 2004, 24 (5D) : 3535 - 3535
12345